Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Final Word on Diet-Breast Cancer Link Must Come From Clinical Trials: WHI

March 1, 1996
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 3
Volume 5
Issue 3

BETHESDA, Md--Concerned that a New England Journal of Medicine article reporting no link between fat intake and breast cancer might deter women from joining the diet-cancer segment of the NIH-sponsored Women's Health Initiative (WHI), its top leaders took an unusual step.

BETHESDA, Md--Concerned that a New England Journal of Medicinearticle reporting no link between fat intake and breast cancermight deter women from joining the diet-cancer segment of theNIH-sponsored Women's Health Initiative (WHI), its top leaderstook an unusual step.

They issued a press statement that challenges, not the article'sfindings, but the notion that the question of whether dietaryfat contributes to the development of breast cancer can be answeredoutside of a randomized clinical trial.

"Numerous other studies . . . support such a link,"the statement said. "The WHI trial is designed to answerconfidently this and other important questions related to women'shealth."

The article, which appeared in the February 8, 1996, issue ofthe Journal and garnered extensive media attention, detailed areanalysis of seven cohort studies that had investigated the linkbetween fat and breast cancer. The studies involved a total of337,819 women.

"We found no evidence of a positive association between totaldietary fat intake and the risk of breast cancer," said leadauthor David J. Hunter of the Harvard School of Public Health."There was no reduction in risk even among women whose energyintake from fat was less than 20% of total energy intake."

The article noted, and the WHI statement emphasized, that othertypes of studies have reached contrary conclusions. These includeepidemiologic studies, comparisons of women living in one countrywith those from that country who have migrated to another andchanged their diet, case-control studies, and animal feeding trials.

This leads to the possibility that the new findings might resultfrom some defect within cohort studies themselves, the WHI statementsaid. In cohort studies, the amount of fat is estimated priorto the development of a breast tumor; in case-control studies,the estimate comes after the cancer appears. Cohort studies generallyget the nod over case-control studies as the more reliable. However,"neither of these types of studies is as reliable as a clinicaltrial," the WHI said.

In an interview with Oncology News International, WHI directorDr. Loretta Finnegan and Dr. Jacques Rossouw, WHI's lead projectofficer, acknowledged their concern that women who heard aboutthe conclusions of the cohort reanalysis might refuse to joinWHI's study.

"Women might be advised by their physicians that it's notworth participating in the trial because it's not likely to succeed,"Dr. Rossouw said. "We don't agree. We think there is a reasonablystrong hypothesis that changing the diet will lower cancer risks."

Dr. Finnegan emphasized that the final word on the subject shouldbe based on "what we call the gold standard, which is theclinical trial, which is the WHI trial."

More than 16,000 women, aged 50 to 79, have enrolled in the dietarycomponent of the WHI at 40 clinical centers nationwide; officialshope that 48,000 will sign up before enrollment ends early in1998. The women will be followed for 9 years.

"What we're testing is whether a total dietary pattern, whichincludes reduction in dietary fats but also increases in fruits,vegetables, and grains, has health benefits for preventing breastcancer, colorectal cancer, and heart disease," Dr. Rossouwsaid.

Women can obtain information on participating in the WHI dietarystudy by calling 1-800-54-WOMEN.

Articles in this issue

Drug Allows Higher Doxorubicin Doses in Breast Ca Patients
Nori Appointed to Cornell Department of Radiation Oncology
Academic Centers Must Change or Perish in Climate of Managed Care
Genetically Altered Hematopoietic Cells Used in Transplant Research
Bill Would Ease Distribution of Off-Label Data
New Critical Pathway Reduces the Costs of Radical Prostatectomy at Chicago Hospital
New Drug Combinations May Improve Outlook in AIDS Patients
Dose-Intense Chemo in Breast Ca Questioned
Final Word on Diet-Breast Cancer Link Must Come From Clinical Trials: WHI
LHRH Agonist Matches Ovariectomy Results: SWOG
Schacter Named Clinical Trials Director at Yale
Newer Strategies Aim to Improve Long-Term Remission Rates in AML
Genetic Suppressor Elements Proving Useful in Drug Resistance Research
Dr. Vogel to Lead Joint Breast Cancer Program
Alternatives to Fee for Service Involve Risks
Recent Videos
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
3 experts in this video
Related Content
Advertisement

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

Sheng Chow;Meredith Shamamian;Susan Laura Jao;Andreina Giron;Jessica Lin;Fardeen Bhimani;Eleni Kohilakis;Caroline Oska;Jana Fox;Sheldon Feldman;Maureen McEvoy
May 14th 2025
Article

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


Recent ADC Approvals and Their Impact on the Breast Cancer Space

Recent ADC Approvals and Their Impact on the Breast Cancer Space

Neil M. Iyengar, MD
May 13th 2025
Article

Neil M. Iyengar, MD, highlighted the recent T-DXd and Dato-DXd approvals in breast cancer.


Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

Allen Gee;Grace Oh;June Lee
May 12th 2025
Article

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

Ken Weixing Ho;Nicholas Holford;Rathi Ramakrishnan;Patriek Jurrius;Sarah Pinder;Arnie Purushotham;Daniel Leff
May 11th 2025
Article
Related Content
Advertisement

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

Sheng Chow;Meredith Shamamian;Susan Laura Jao;Andreina Giron;Jessica Lin;Fardeen Bhimani;Eleni Kohilakis;Caroline Oska;Jana Fox;Sheldon Feldman;Maureen McEvoy
May 14th 2025
Article

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


Recent ADC Approvals and Their Impact on the Breast Cancer Space

Recent ADC Approvals and Their Impact on the Breast Cancer Space

Neil M. Iyengar, MD
May 13th 2025
Article

Neil M. Iyengar, MD, highlighted the recent T-DXd and Dato-DXd approvals in breast cancer.


Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

Allen Gee;Grace Oh;June Lee
May 12th 2025
Article

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

Ken Weixing Ho;Nicholas Holford;Rathi Ramakrishnan;Patriek Jurrius;Sarah Pinder;Arnie Purushotham;Daniel Leff
May 11th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.